Inositol

Summary

Inositol (CHEMBL1222251) is a phase-3 clinical-stage small-molecule EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor (ATC A11HA07); indicated across 10 conditions including retinopathy of prematurity and type 1 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A11HA07
• Indications: 10 conditions
• Clinical trials: 66
• Chemistry: 180.16 Da · C6H12O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1222251
Name	Inositol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	892
ChEBI	CHEBI:17268
ATC	A11HA07
Molecular formula	C6H12O6
Molecular weight	180.16
InChIKey	CDAISMWEOUEBRE-UHFFFAOYSA-N

SMILES: C1(C(C(C(C(C1O)O)O)O)O)O

IUPAC name: cyclohexane-1,2,3,4,5,6-hexol

ChEBI definition: An inositol having myo- configuration.

Pharmacological roles (ChEBI): nutrient, EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor.

Other ChEBI roles (chemical / environmental): human metabolite, Daphnia magna metabolite, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: Cyclohexanehexol, I-inositol, Inositol, myo, myo-, Meso-inositol, Myo-inositol, NSC-25142, NSC-404118, NSC-55551, NSC-8101, myo-inositol

Patent coverage: 71,127 distinct patent families (191,966 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5	Potency	10000	nM	CHEMBL_ACT_3662765

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
retinopathy of prematurity	3	MONDO:0006952	EFO:1001158
type 1 diabetes mellitus	3	MONDO:0005147	MONDO:0005147
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
metabolic syndrome X	2	MONDO:0011565	EFO:0000195
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
trichotillomania	2	MONDO:0013189	MONDO:0013189
lung neoplasm	1	MONDO:0021117	MONDO:0008903
neural tube defect	1	MONDO:0018075	MONDO:0018075
polycystic ovary syndrome	0	MONDO:0008487	EFO:0000660

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 66.

Phase distribution

Phase	Trials
Not specified	36
PHASE4	13
PHASE2	5
PHASE2/PHASE3	3
PHASE3	3
PHASE1/PHASE2	2
PHASE1	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01267604	PHASE4	WITHDRAWN	Ovarian Stimulation: Inositol and Melatonin
NCT01338844	PHASE4	COMPLETED	Role of Myo-inositol and D-chiro-inositol on Oocyte Quality
NCT01396486	PHASE4	COMPLETED	Inositol and Omega-3 Fatty Acids in Pediatric Mania
NCT01511835	PHASE4	UNKNOWN	Efficacy of Myo-inositol in Preventing Gestational Diabetes in High-risk Pregnant Women
NCT01514942	PHASE4	COMPLETED	Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters
NCT01540747	PHASE4	COMPLETED	Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome
NCT01560065	PHASE4	COMPLETED	Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing In Vitro Fertilization Cycles
NCT01626443	PHASE4	COMPLETED	Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions
NCT02418130	PHASE4	COMPLETED	A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ‘Ursa Complex Soft Cap. (UDCA-004)’ in Patients With Physical Fatigue.
NCT03177122	PHASE4	UNKNOWN	Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT03911414	PHASE4	COMPLETED	A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth
NCT04306692	PHASE4	TERMINATED	Myo-inositol Versus Clomiphene Citrate in PCOS
NCT03059173	PHASE3	RECRUITING	Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
NCT01115127	PHASE2/PHASE3	COMPLETED	Myo-inositol and Melatonin in Pre-menopausal Women
NCT01954082	PHASE3	TERMINATED	Inositol to Reduce Retinopathy of Prematurity
NCT03767569	PHASE3	UNKNOWN	Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients
NCT04273256	PHASE2/PHASE3	UNKNOWN	Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial
NCT05900661	PHASE2/PHASE3	UNKNOWN	The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders
NCT00783705	PHASE2	COMPLETED	Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
NCT01046500	PHASE2	UNKNOWN	Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome
NCT01111292	PHASE1/PHASE2	TERMINATED	Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
NCT01875445	PHASE2	COMPLETED	Inositol in Trichotillomania
NCT02633462	PHASE2	UNKNOWN	Non-surgical Periodontal Therapy and Myo-inositol in Polycystic Ovary Syndrome Women Having Chronic Periodontitis
NCT02811133	PHASE1/PHASE2	WITHDRAWN	Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder
NCT03864068	PHASE2	COMPLETED	Inositol Supplementation to Treat PCOS (INSUPP-PCOS)
NCT00061997	PHASE1	COMPLETED	Inositol in Preventing Lung Cancer in Patients With Bronchial Epithelial Dysplasia Who Are Current or Former Smokers
NCT00452829	PHASE1	COMPLETED	Prevention of Neural Tube Defects by Inositol in Conjunction With Folic Acid (PONTI Study)
NCT01574261	EARLY_PHASE1	UNKNOWN	Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial
NCT04204044	EARLY_PHASE1	UNKNOWN	Comparison of Myoinositol and Metformin in PCO
NCT03585738	Not specified	NOT_YET_RECRUITING	Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women
NCT04407754	Not specified	ACTIVE_NOT_RECRUITING	Myo-Inositol for Infertility in PCOS
NCT06575868	Not specified	RECRUITING	Myo-inositol During Pregnancy to Prevent Gestational Diabetes
NCT06840613	Not specified	NOT_YET_RECRUITING	Glucophage Plus Myo-Inositol vs Glucophage in Glycemic Control Among Patients With Gestational Diabetes Mellitus
NCT07241221	Not specified	RECRUITING	Antenatal Myo-inositol Supplementation in Pre-existing Diabetes
NCT07257770	Not specified	RECRUITING	Local Treatment of Breast Pain Based on the Daily Use of a Topical Gel
NCT00012558	Not specified	COMPLETED	Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
NCT00734448	Not specified	UNKNOWN	Myo-inositol Administration in Gestational Diabetes
NCT01047982	Not specified	COMPLETED	Myo-inositol in Obese Pregnant Women
NCT01244399	Not specified	COMPLETED	Influence of Espresso on Adsorption of Myo-inositol

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).